CELESTE SORAH: Open Payments
NPI 1790101558 · BRISTOL, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,043 in 43 payments from 14 companies in 2025. Trend: 2023 $1,255 · 2024 $1,370 · 2025 $1,043
Food & beverage: $1,043
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $198 |
| Regeneron Healthcare Solutions, Inc. | 5 | $142 |
| Viatris Specialty LLC | 5 | $103 |
| Merck Sharp & Dohme LLC | 3 | $98 |
| Grifols USA, LLC | 3 | $81 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $75 |
| Insmed, Inc. | 3 | $75 |
| United Therapeutics Corporation | 2 | $58 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| La Jolla Pharmaceutical Company | 2 | $46 |
Products named: DUPIXENT, YUPELRI, ZERBAXA, Prolastin-C Liquid, Arikayce, BREZTRI, OFEV, Tyvaso.
Industry payments across TN — which companies pay providers there.
